[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554028":3},{"organization":4,"armGroups":7,"interventions":38,"overallOfficials":11,"centralContacts":11,"locations":61,"responsibleParty":82,"collaborators":11,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":11,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":11,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","INDUSTRY",[8,16,21,24,27,30,35],{"label":9,"type":10,"description":11,"interventionNames":12},"SSGJ-707(dose 1)+ XELOX","EXPERIMENTAL",null,[13,14,15],"Drug: SSGJ-707","Drug: Oxaliplatin","Drug: Capecitabine",{"label":17,"type":10,"description":11,"interventionNames":18},"SSGJ-707(dose 1)+ mFOLFOX6",[13,14,19,20],"Drug: Calcium Folinate","Drug: 5-fluorouracil",{"label":22,"type":10,"description":11,"interventionNames":23},"SSGJ-707(dose 2)+ XELOX",[13,14,15],{"label":25,"type":10,"description":11,"interventionNames":26},"SSGJ-707(dose 2)+ mFOLFOX6",[13,14,19,20],{"label":28,"type":10,"description":11,"interventionNames":29},"SSGJ-707+XELOX\u002FmFOLFOX6",[13,14,15,19,20],{"label":31,"type":32,"description":11,"interventionNames":33},"Bevacizumab+XELOX\u002FmFOLFOX6","ACTIVE_COMPARATOR",[34,14,15,19,20],"Drug: Bevacizumab",{"label":36,"type":10,"description":11,"interventionNames":37},"SSGJ-707 monotherapy",[13],[39,44,48,52,55,58],{"type":40,"name":41,"description":42,"armGroupLabels":43,"otherNames":11},"DRUG","SSGJ-707","bispecific antibody",[36,9,17,22,25,28],{"type":40,"name":45,"description":46,"armGroupLabels":47,"otherNames":11},"Bevacizumab","VEGF antibody",[31],{"type":40,"name":49,"description":50,"armGroupLabels":51,"otherNames":11},"Oxaliplatin","chemotherapy",[31,9,17,22,25,28],{"type":40,"name":53,"description":50,"armGroupLabels":54,"otherNames":11},"Capecitabine",[31,9,22,28],{"type":40,"name":56,"description":50,"armGroupLabels":57,"otherNames":11},"Calcium Folinate",[31,17,25,28],{"type":40,"name":59,"description":50,"armGroupLabels":60,"otherNames":11},"5-fluorouracil",[31,17,25,28],[62],{"facility":63,"status":64,"city":65,"state":66,"zip":11,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Liu Tianshu","RECRUITING","Shanghai","Shanghai Municipality","China","CN",{"type":70,"coordinates":71},"Point",[72,73],121.45806,31.22222,{"lat":73,"lon":72},[76,81],{"name":77,"role":78,"phone":79,"phoneExt":11,"email":80},"Liu Tianshu, PhD","CONTACT","13681973996","liu.tianshu@zs-hospital.sh.cn",{"name":77,"role":78,"phone":11,"phoneExt":11,"email":11},{"type":83,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100554028","phase-2-a-phase-2-study-of-ssgj-707-in-metastatic-colorectal-cancer-patients-100554028",false,"NCT06493760","A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 As First-Line Treatment in Metastatic Colorectal Cancer Patients","Inclusion Criteria:\n\n1. Males and\u002For females over age 18\n2. Histologically and\u002For cytologically documented metastatic colorectal cancer confirmed .\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n4. Expected survival \\>=12 weeks.\n5. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Known uncontrolled or symptomatic central nervous system metastatic disease.\n2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \\>1 (National Cancer Institute Common terminology Criteria \\[NCI CTCAE\\] v.5.0).\n3. Inadequate organ or bone marrow function.\n4. Pregnant or breast-feeding woman.\n5. Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":95,"type":96},130,"ESTIMATED","INTERVENTIONAL",[99],"PHASE2","This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.",[102],"Metastatic Colorectal Cancer",[41,104],"colorectal cancer","2024-09-04",{"date":107,"type":108},"2024-09-19","ACTUAL",{"date":110,"type":108},"2024-09-03",{"date":112,"type":96},"2027-06",{"name":5,"class":6},1]